Vireo Growth (VREOF) Other financing activities (2021 - 2025)

Vireo Growth (VREOF) reported Other financing activities of $15406.0 for Q2 2025, down 33.34% sequentially from $23110.0 in Q1 2025.

Vireo Growth (VREOF) Other financing activities (2021 - 2025) Analysis & Trends

Vireo Growth (VREOF) has 3 years of Other financing activities data on file, last reported at $15406.0 in Q2 2025.

  • For the quarter ending Q2 2025, Other financing activities changed N/A year-over-year to $15406.0; the trailing twelve-month figure through Dec 2025 stood at $38516.0 (down 65.04% YoY), and the FY2025 full-year result was $38516.0, down 44.71% from the prior year.
  • Other financing activities retreated to $15406.0 in Q2 2025, from $23110.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $966156.0 in Q1 2021 to a low of $15406.0 in Q2 2025.
  • A 3-year average of $185897.7 and a median of $57009.0 in 2021 frame the typical range for Other financing activities.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn

Historic Data

Download Data
DateValue
Jun 30, 2025 15,406.00
Jun 30, 2025 15,406.00
Mar 31, 2025 23,110.00
Mar 31, 2025 23,110.00
Dec 31, 2024 53,163.00
Dec 31, 2024 53,163.00
Dec 31, 2021 57,009.00
Dec 31, 2021 57,009.00
Sep 30, 2021 76,873.00
Sep 30, 2021 76,873.00
Jun 30, 2021 109,567.00
Jun 30, 2021 109,567.00
Mar 31, 2021 966,156.00
Mar 31, 2021 966,156.00